NE3107 Trial in Adults with Long COVID Symptoms
Phase 2
208
about 9 months
18–69
20 sites in CA, CO, CT +14
About this study
This trial is testing NE3107, a medication, to see if it helps treat neurological symptoms like brain fog and fatigue that can persist after a COVID-19 infection. Researchers will compare NE3107 to a placebo (a look-alike substance) to determine if NE3107 works to improve neurocognitive and fatigue symptoms of long COVID. Participants will take NE3107 or a placebo twice daily for 84 days, visit the clinic multiple times for checkups and tests, and have follow up phone calls.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take NE3107
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Change from Baseline in performance on the Cogstate Cognition battery
Secondary: Change from Baseline in DePaul Symptom Questionnaire (DSQ) Post-Exertional Malaise (PEM, Change from Baseline in PROMIS Cognitive Function Short Form 8a (SF-8a), Change from Baseline in PROMIS Fatigue Short Form 13a (SF-13a), Change from Baseline in PROMIS Sleep Disturbance Short Form 8a (SF-8a), Change from Baseline in SF-12 Health Survey (Physical and Mental Component Scores)